This preview shows page 1. Sign up to view the full content.
Unformatted text preview: ty of data in doubt with active-control trials but also the ‘‘quality’’ of research subjects. Researchers must standardize medical histories if they are to ensure their comparability—time-consuming, costly, and all but impossible tasks. Temple’s invalidation of the active-control trial is anthropologically and economically significant—the treat¨ ment naıve become preferable from a regulatory standpoint that emphasizes the importance of an efficient (and foolproof) global research subject. Precisely because they are often poor, without a treatment history, and without ¨ treatment, the treatment naıve are the more foolproof and valuable research subjects! 188...
View Full Document
This note was uploaded on 10/10/2010 for the course ENG 000121 taught by Professor Mcgrand during the Spring '10 term at Cornell University (Engineering School).
- Spring '10